Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
Journal
Oncology
Journal Volume
99
Journal Issue
1
Pages
32
Date Issued
2021
Author(s)
Tseng, Jeng-Sen
Hsu, Kuo-Hsuan
Zheng, Zhe-Rong
Yang, Tsung-Ying
Chen, Kun-Chieh
Huang, Yen-Hsiang
Chang, Gee-Chen
Abstract
The characteristics and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in advanced EGFR-mutant lung adenocarcinoma patients with primary tumor resection (PTR) is not yet clear.
Subjects
Epidermal growth factor receptor; Epidermal growth factor receptor-tyrosine kinase inhibitor; Local ablative therapy; Lung adenocarcinoma; Primary tumor resection
SDGs
Other Subjects
bevacizumab; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; protein tyrosine kinase inhibitor; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; ablation therapy; adult; advanced cancer; aged; Artic
Publisher
KARGER
Type
journal article